Previous studies that have examined ctDNA in NSCLC patients with resistance to EGFR TKIs have primarily used techniques limited to interrogating mutations in EGFR16, 49, 50, 51, 52, 53, 54, and therefore were unable to detect SCNAs in bypass pathway genes such as MET. This evidence concerns the gene EGFR and non-small cell lung carcinoma.